Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (191)	6/3/1998 4:13:00 PM
From: Anthony Wong	Respond to of 1722

Pfizer Gets Approval To Market Allergy Drug To Children Over Age Two June 03, 1998 11:42 AM NEW YORK -(Dow Jones)- Pfizer Inc. and UCB Pharma Inc. said Wednesday their Zyrtec allergy drug won Food and Drug Administration approval to be used in children two and older. The drug was initially approved for patients age 12 and older in January 1996 and was approved for children over six in September 1996. The company said Zyrtec is available in a one milligram per one milliliter banana-grape flavor syrup and in 5-mg and 10-mg tablets. Pfizer (PFE) and UCB Pharma co-promote Zyrtec in the U.S. UCB makets Zyrtec world-wide. UCB Pharma is a unit of UCB SA, a Belgium pharmaceuticals, chemicals and film company. Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.

To: Anthony Wong who wrote (191)	6/3/1998 4:14:00 PM
From: Anthony Wong	Read Replies (3) \| Respond to of 1722

Shares Of Some Impotence-Drug Makers Slide On Comparison With Viagra June 03, 1998 2:20 PM NEW YORK -(Dow Jones)- Shares of several makers of impotence drugs were under pressure Wednesday after a story in The Wall Street Journal reported that patients' first choice will likely be Pfizer Inc.'s blockbuster Viagra, despite the success of other drugs. The article mentioned Zonagen Inc., MacroChem Corp. and Vivus Inc., which all have clinical trial results on their products being presented this week at the American Urological Association meeting in San Diego. Researchers said that none of the other drugs has been directly compared with Viagra. However, they all have more side effects or are more difficult to use than Viagra, the article said. "The stocks are definitely reacting to the Journal article and not the clinical results," said Edmund Debler, an analyst at Mehta Partners. At the Urological Association meeting Tuesday, researchers presented data that indicated Zonagen's oral drug Vasomax was well tolerated in Phase III, or late-stage, trials. Researchers also said Tuesday that data from a new study confirms the safety and efficacy of MacroChem's Topiglan gel for treatment of erectile dysfunction. Data was presented Tuesday that indicated Vivus's Muse treatment, which is inserted directly into the urethra, was less effective than had been believed. In afternoon trading, shares of Vivus (VVUS) were down $1.563, or 18%, at $7.188. MacroChem (MCHM) shares slipped 43.8 cents, or 3.9%, to $10.938, and shares of Zonagen (ZONA) declined $4.688, or 13%, to $32.063. TAP Holdings Inc. was also mentioned in the article. The company, a joint venture of Abbott Laboratories and Takeda Chemical Industries Ltd. of Japan, is developing apomorphine, which acts directly on the brain to create erections. However, shares of Abbott Labs (ABT) were up 12.5 cents at $36.688. -By Jennifer Fron Mauer; 201-938-5287; jennifer-fron.mauer@cor.dowjones.com Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.